Hepatitis B

Positive results reported from phase I/II trial of ANA380 (LB80380)

Published in Hepatitis Weekly, December 6th, 2004

Anadys Pharmaceuticals, Inc., (ANDS) and LG Life Sciences, Ltd., (KOSPI: 68870) reported results from a recently completed phase I/II clinical trial of ANA380 (LB80380), an orally available compound for the treatment of hepatitis B virus (HBV) infection, at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston.

In a presentation entitled "phase I/II Double-Blind, Randomized, Placebo-Controlled Study of the Novel Anti-HBV Agent LB80380/ANA380 in Patients with Chronic HBV Infection," Man-Fung Yuen of the University of Hong Kong reported that ANA380 reduced viral load by an average of 3.4 log10 units, or more than 99.9%, in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry